Timothy D Malouff1, Jennifer L Peterson1,2, Anita Mahajan3, Daniel M Trifiletti4,5. 1. Department of Radiation Oncology, Mayo Clinic Florida, 4500 San Pablo Road S, Mayo 1N, Jacksonville, FL, 32224, USA. 2. Department of Neurological Surgery, Mayo Clinic, Jacksonville, FL, USA. 3. Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA. 4. Department of Radiation Oncology, Mayo Clinic Florida, 4500 San Pablo Road S, Mayo 1N, Jacksonville, FL, 32224, USA. trifiletti.daniel@mayo.edu. 5. Department of Neurological Surgery, Mayo Clinic, Jacksonville, FL, USA. trifiletti.daniel@mayo.edu.
Abstract
INTRODUCTION: Gliomas are among the most common primary brain malignancies, with a poor prognosis for high grade gliomas despite aggressive therapy. Carbon ions, which exhibit favorable biological and physical characteristics, have recently been studied in intracranial malignancies as a way to escalate dose to the tumor while minimizing dose to normal tissue. METHODS: Pubmed/Medline, SCOPUS, EMBASE, CINAHL and the Cochrane database were systematically reviewed using the search terms "carbon ion" and "glioma" or "glioblastoma" in August 2019. Out of 332 articles screened, 43 were included in this analysis. RESULTS: This comprehensive review describes the pertinent physics and radiation biology studies relevant to the treatment of gliomas with carbon ions and summarizes the important clinical studies for both high and low grade gliomas. Studies investigating carbon ions as both definitive radiotherapy and as a boost to traditional radiotherapy are reviewed. The use of carbon ion radiotherapy in the setting of recurrent disease is also described. CONCLUSIONS: Carbon ion radiotherapy is both efficacious and safe based on early clinical studies. Current trials, including the CLEOPATRA and CINDERLLA trials, hope to define the role of carbon ion radiotherapy in the treatment of gliomas.
INTRODUCTION:Gliomas are among the most common primary brain malignancies, with a poor prognosis for high grade gliomas despite aggressive therapy. Carbon ions, which exhibit favorable biological and physical characteristics, have recently been studied in intracranial malignancies as a way to escalate dose to the tumor while minimizing dose to normal tissue. METHODS: Pubmed/Medline, SCOPUS, EMBASE, CINAHL and the Cochrane database were systematically reviewed using the search terms "carbon ion" and "glioma" or "glioblastoma" in August 2019. Out of 332 articles screened, 43 were included in this analysis. RESULTS: This comprehensive review describes the pertinent physics and radiation biology studies relevant to the treatment of gliomas with carbon ions and summarizes the important clinical studies for both high and low grade gliomas. Studies investigating carbon ions as both definitive radiotherapy and as a boost to traditional radiotherapy are reviewed. The use of carbon ion radiotherapy in the setting of recurrent disease is also described. CONCLUSIONS:Carbon ion radiotherapy is both efficacious and safe based on early clinical studies. Current trials, including the CLEOPATRA and CINDERLLA trials, hope to define the role of carbon ion radiotherapy in the treatment of gliomas.
Authors: Maximilian Niyazi; Michael Brada; Anthony J Chalmers; Stephanie E Combs; Sara C Erridge; Alba Fiorentino; Anca L Grosu; Frank J Lagerwaard; Giuseppe Minniti; René-Olivier Mirimanoff; Umberto Ricardi; Susan C Short; Damien C Weber; Claus Belka Journal: Radiother Oncol Date: 2016-01-06 Impact factor: 6.280
Authors: J Morini; G Babini; S Barbieri; G Baiocco; M Ciocca; G B Ivaldi; M Liotta; S Molinelli; P Tabarelli de Fatis; A Ottolenghi Journal: Radiat Prot Dosimetry Date: 2019-05-01 Impact factor: 0.972
Authors: D Maucort-Boulch; M-H Baron; P Pommier; D C Weber; J-E Mizoe; J Rochat; J-P Boissel; J Balosso; H Tsujii; E Amsallem Journal: Cancer Radiother Date: 2009-12-08 Impact factor: 1.018
Authors: Stephanie E Combs; Kerstin Kessel; Daniel Habermehl; Thomas Haberer; Oliver Jäkel; Jürgen Debus Journal: Acta Oncol Date: 2013-08-21 Impact factor: 4.089
Authors: J Nathan Cantrell; Mark R Waddle; Maarten Rotman; Jennifer L Peterson; Henry Ruiz-Garcia; Michael G Heckman; Alfredo Quiñones-Hinojosa; Steven S Rosenfeld; Paul D Brown; Daniel M Trifiletti Journal: Mayo Clin Proc Date: 2019-06-20 Impact factor: 7.616
Authors: Stefan Rieken; Daniel Habermehl; Thomas Haberer; Oliver Jaekel; Jürgen Debus; Stephanie E Combs Journal: Radiat Oncol Date: 2012-03-21 Impact factor: 3.481
Authors: Osama Mohamad; Brock J Sishc; Janapriya Saha; Arnold Pompos; Asal Rahimi; Michael D Story; Anthony J Davis; D W Nathan Kim Journal: Cancers (Basel) Date: 2017-06-09 Impact factor: 6.639
Authors: Yang Liu; Yuanyuan Liu; Chao Sun; Lu Gan; Luwei Zhang; Aihong Mao; Yuting Du; Rong Zhou; Hong Zhang Journal: PLoS One Date: 2014-06-03 Impact factor: 3.240
Authors: Alessandra Palma; Sveva Grande; Lucia Ricci-Vitiani; Anna Maria Luciani; Mariachiara Buccarelli; Mauro Biffoni; Valentina Dini; Giuseppe A P Cirrone; Mario Ciocca; Laura Guidoni; Roberto Pallini; Vincenza Viti; Antonella Rosi Journal: Int J Mol Sci Date: 2020-07-21 Impact factor: 5.923
Authors: Michael Weller; Martin van den Bent; Matthias Preusser; Emilie Le Rhun; Jörg C Tonn; Giuseppe Minniti; Martin Bendszus; Carmen Balana; Olivier Chinot; Linda Dirven; Pim French; Monika E Hegi; Asgeir S Jakola; Michael Platten; Patrick Roth; Roberta Rudà; Susan Short; Marion Smits; Martin J B Taphoorn; Andreas von Deimling; Manfred Westphal; Riccardo Soffietti; Guido Reifenberger; Wolfgang Wick Journal: Nat Rev Clin Oncol Date: 2020-12-08 Impact factor: 66.675
Authors: Augusto Leone; Antonio Colamaria; Nicola Pio Fochi; Matteo Sacco; Matteo Landriscina; Giovanni Parbonetti; Matteo de Notaris; Giulia Coppola; Elena De Santis; Guido Giordano; Francesco Carbone Journal: Biomedicines Date: 2022-08-09
Authors: Maria Waltenberger; Jennifer Furkel; Manuel Röhrich; Patrick Salome; Charlotte Debus; Bouchra Tawk; Aoife Ward Gahlawat; Andreas Kudak; Matthias Dostal; Ute Wirkner; Christian Schwager; Christel Herold-Mende; Stephanie E Combs; Laila König; Jürgen Debus; Uwe Haberkorn; Amir Abdollahi; Maximilian Knoll Journal: Front Oncol Date: 2022-09-20 Impact factor: 5.738